News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
808,050 Results
Type
Article (74024)
Company Profile (698)
Press Release (733328)
Section
Business (227302)
Career Advice (3714)
Deals (39296)
Drug Delivery (122)
Drug Development (89206)
Employer Resources (194)
FDA (17777)
Job Trends (17091)
News (387416)
Policy (38716)
Tag
Academia (2974)
Alliances (55810)
Alzheimer's disease (1398)
Approvals (17708)
Artificial intelligence (197)
Bankruptcy (394)
Best Places to Work (12599)
Biotechnology (478)
Breast cancer (219)
Cancer (1648)
Cardiovascular disease (141)
Career advice (3159)
Cell therapy (355)
Clinical research (71128)
Collaboration (629)
Compensation (319)
COVID-19 (2824)
C-suite (147)
Data (1514)
Diabetes (211)
Diagnostics (6742)
Earnings (92281)
Employer resources (167)
Events (126683)
Executive appointments (522)
FDA (18597)
Funding (554)
Gene therapy (247)
GLP-1 (748)
Government (5025)
Healthcare (20790)
Infectious disease (2931)
Inflammatory bowel disease (129)
Interviews (722)
IPO (17627)
Job creations (4986)
Job search strategy (2592)
Layoffs (501)
Legal (9878)
Lung cancer (247)
Manufacturing (244)
Medical device (14468)
Medtech (14473)
Mergers & acquisitions (21914)
Metabolic disorders (576)
Neuroscience (1806)
NextGen: Class of 2025 (7627)
Non-profit (5071)
Northern California (1925)
Obesity (328)
Opinion (253)
Patents (144)
People (63401)
Pharmaceutical (143)
Phase I (21959)
Phase II (31019)
Phase III (23386)
Pipeline (639)
Postmarket research (3272)
Preclinical (9664)
Radiopharmaceuticals (261)
Rare diseases (323)
Real estate (7137)
Regulatory (25556)
Research institute (2644)
Resumes & cover letters (581)
Southern California (1675)
Startups (4189)
United States (17934)
Vaccines (686)
Weight loss (254)
Date
Today (115)
Last 7 days (462)
Last 30 days (2113)
Last 365 days (37489)
2025 (1980)
2024 (37951)
2023 (42567)
2022 (53926)
2021 (58723)
2020 (57667)
2019 (51311)
2018 (39093)
2017 (36839)
2016 (37748)
2015 (43742)
2014 (38439)
2013 (34423)
2012 (36329)
2011 (36449)
2010 (35886)
Location
Africa (1186)
Arizona (218)
Asia (48212)
Australia (8306)
California (4505)
Canada (1590)
China (384)
Colorado (206)
Connecticut (229)
Europe (108674)
Florida (627)
Georgia (158)
Illinois (484)
Indiana (264)
Maryland (749)
Massachusetts (3578)
Michigan (206)
Minnesota (344)
New Jersey (1258)
New York (1256)
North Carolina (929)
Northern California (1925)
Ohio (167)
Pennsylvania (1033)
South America (1565)
Southern California (1675)
Texas (665)
Utah (129)
Washington State (467)
808,050 Results for "kubota pharmaceutical holdings co ltd".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Lakeside Holding Enters Medical Logistics Sector with Acquisition of Hupan Pharmaceutical (Hubei) Co., Ltd.
November 11, 2024
·
4 min read
BioForest
Kubota Vision Announces Agreement with AUROLAB for Development, Manufacturing, Supply, and Distribution License of eyeMO
Kubota Vision Inc., a clinical-stage specialty ophthalmology company and a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd., announced the execution of a collaboration letter of intent between Kubota Vision and AUROLAB.
December 6, 2023
·
4 min read
BioForest
Kubota Vision Announces Vendor Agreement with IQVIA for eyeMO
Kubota Vision Inc., a clinical-stage specialty ophthalmology company and a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd., announced the execution of a vendor agreement between Kubota Vision and IQVIA Services Japan G.K. for eyeMO, a portable, low-cost, home-based, remote and in-office ophthalmic OCT*1 device for monitoring of retinal diseases.
December 6, 2023
·
3 min read
BioForest
Kubota Vision Announces Collaborative Research Agreement with China Medical University Hsinchu Hospital
Kubota Vision Inc., a clinical-stage specialty ophthalmology company and a wholly owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd., announced the execution of a collaborative research agreement between Kubota Vision and China Medical University Hsinchu Hospital, Department of Ophthalmology, for a study using Kubota Glass in Taiwan, led by Dr. Ying-Shan Chen.
September 7, 2023
·
3 min read
BioCapital
Vanda Pharmaceuticals Confirms Receipt of Unsolicited, Non-Binding Indication of Interest from Cycle Group Holdings Ltd.
Vanda Pharmaceuticals Inc. confirmed that it has received an unsolicited, non-binding indication of interest from Cycle Group Holdings Ltd. to acquire the Company for $8.00 per share in cash.
June 6, 2024
·
3 min read
Press Releases
Meiji Seika Pharma: Announcement of the Establishment of Local Subsidiary “Taiwan Meiji Pharma Co., Ltd.” in Taiwan
December 25, 2024
·
1 min read
Press Releases
Park Ha Biological Technology Co., Ltd. Announces Closing of $4.8 Million Initial Public Offering
December 31, 2024
·
4 min read
Business
Verrica Pharmaceuticals Announces Amendment to Company’s Collaboration and License Agreement with Torii Pharmaceutical Co. Ltd. to Fund Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common Warts
Verrica Pharmaceuticals Inc. today announced that it has entered into an amendment to its existing licensing agreement with Torii Pharmaceutical Co. Ltd. (Torii), to jointly conduct a global pivotal Phase 3 clinical trial of YCANTH® for the treatment of common warts.
May 15, 2024
·
9 min read
Press Releases
Park Ha Biological Technology Co., Ltd. Announces Pricing of $4.8 Million Initial Public Offering
December 26, 2024
·
4 min read
Press Releases
Newron and EA Pharma (A Subsidiary of Eisai Co., Ltd.) Announce License Agreement for Evenamide in Japan and Other Asian Territories
December 13, 2024
·
11 min read
1 of 80,805
Next